D.Western Therapeutics Institute, Inc. (4576) Stock Price

De Western Therapeutics Institute conducts research and development of pharmaceuticals, primarily focused on protein kinase inhibitors. The company generates revenue through its drug discovery business by licensing developed pharmaceuticals to pharmaceutical companies. Together with its consolidated subsidiary, Japan Innovation Pharmaceuticals Inc., the company advances efficient research and development.

De Western Therapeutics Institute's drug discovery business employs a business model that reduces development costs while generating revenue by progressing from basic research through non-clinical and clinical trials before licensing out to pharmaceutical companies. This approach allows the company to maintain a low-cost development structure as pharmaceutical companies advance clinical development.

De Western Therapeutics Institute's revenue consists of upfront payments at the time of licensing out, milestone payments as clinical development progresses, and royalty income following product commercialization. Products such as "DW-1002" and "Granatect" have already been licensed out and are generating revenue.

The company's development pipeline includes ophthalmic therapeutic agents and glaucoma treatment drugs. For example, "DW-1002" is a product targeting internal limiting membrane staining and is marketed in Europe and the United States. Additionally, "Granatect" has been launched in Japan and Asia as a treatment for glaucoma and ocular hypertension.

De Western Therapeutics Institute creates new drug candidate compounds centered on protein kinase inhibitors, with particular focus on research into ophthalmic-related diseases. By leveraging proprietary technology and conducting efficient research and development, the company realizes early-stage licensing out.

De Western Therapeutics Institute pursues the vision of "bringing groundbreaking new drugs developed in Japan to the world." The company focuses its research and development efforts on protein kinase inhibitors and aims to become a leading drug discovery bioventure.

The company's growth strategy centers on shifting toward a research and development-driven business model. Beyond conducting research based on its own technology, the company actively pursues in-licensing from other companies to expand its development pipeline and maximize revenue from out-licensing.

The drug development environment is becoming increasingly competitive as technological innovation advances. De Western Therapeutics Institute strengthens its competitiveness in biopharmaceutical research and development through pipeline expansion and collaboration with other companies, aiming for continuous creation of new drugs.

The company sets development pipeline progress as a key management metric and focuses on creating high-revenue new drug candidates, in-licensing, and advancing clinical development. Through these efforts, the company expands its development pipeline and allocates management resources to research and development activities.

Priority initiatives include expanding and advancing the development pipeline, broadening business domains, applying core technologies, and strengthening the financial foundation. The company particularly focuses on pipeline expansion through in-licensing activities and expanding the application areas of protein kinase inhibitors.